A CD69-positive CD4+ and CD8+ allogeneic T-cells after treatment of B-NHL samples with epcoritamab (30 ng/mL) and CD3xCtrl (30 ng/mL) in samples with low or high tumor HVEM expression levels (Mann–Whitney U-test; ***p < 0.001, **p < 0.01). B Epcoritamab-dependent cytotoxicity (30 ng/mL) in B-NHL samples with low and high tumor cell HVEM expression (Mann–Whitney U-test; ns). HVEM expression on healthy donor B-cells was used as cut-off value to stratify between low and high expression. Data are shown as median ±interquartile range. All samples from different B-NHL subtypes and from ND and RR are plotted together.